Unknown PHASE2 INTERVENTIONAL 1-arm NCT01811277

SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer

Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer

Sponsor: Peking University

Conditions Biliary Tract Cancer Pancreatic Cancer Periampullary Adenocarcinoma

Interventions SOX sequential S-1

Updated 5 times since 2017 Last updated: Mar 13, 2013 Started: Jul 31, 2010 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Biliary Tract Cancer and Pancreatic Cancer and is currently ongoing. Peking University leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University
Taiho Pharmaceutical Co., Ltd.

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China